Psychedelics
Earlier today the TGA announced its interim decision not to amend the current Poisons Standard in relation to the use of medical grade psilocybin and medical grade MDMA as part of therapy to treat patients suffering from treatment resistant mental illnesses including Depression, PTSD and Substance Abuse. These therapies have been achieving outstanding remission rates […]
Psyched Wellness Provides Update on Antioxidant and Anti-Inflammatory Study of Muscimol
Psyched Wellness Ltd. (CSE:PSYC, OTCQB:PSYCF,FRANKFURT:5U9) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share an update on the previously announced study to determine the therapeutic values of muscimol for antioxidant and anti-inflammatory purposes via a nerve derived immunity and neuroprotective […]
Dr. Roger McIntyre Announces Changes to the Board of Champignon Brands Inc.
Dr. Roger McIntyre, Chairman of the Board of Directors of Champignon Brands Inc. today announces changes to the Champignon Board of Directors (“Champignon“) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF). Bill Wilkerson, LL. D. (Hon), appointed to the Board of Directors of Champignon on May 22, 2020, and elected Vice-Chair of the Board on September 14, […]
Better Plant’s Jusu Begins Expansion into U.S. Market
Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce it has engaged the Thank You Merci’s sales and merchandising team (“TYM“) to represent Jusu Body, Jusu Life, and Jusu Juice; commencing immediately. TYM offers full-service sales representation and key account management for all channels in Canada & the […]
Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, announced today the successful completion of a Type B pre-Investigational New Drug (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding PharmaTher’s clinical […]
PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug“) has entered into a supply agreement (the “Supply Agreement“) on January 4, 2021, with a Canadian based multinational cannabis company for EU-GMP certified medical cannabis. The supply is already registered and approved for sale in the German market. Pursuant to the Supply Agreement, the Company’s licensed German […]
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) a biotechnology research and development company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered into a letter of intent (the “Letter of Intent“) dated January 20, 2021 with Ketamine […]
Cybin Announces Closing of Upsized Bought Deal Offering
Cybin Inc. (NEO:CYBN) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering (the “Offering”), including the exercise of the over-allotment option granted to the Underwriters (as defined herein). In connection with the Offering, the Company issued 15,246,000 units of […]
Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) (“Entheon“, a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Jonna Birgans, a highly experienced media executive and producer, as Vice President of Digital Experience. Mrs. Birgans’ significant depth of experience spans wide across the media […]
Diamond Therapeutics Signs Agreement with McGill University for Research on Low-Dose LSD
Diamond Therapeutics Inc. (“Diamond“), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with McGill University for the exclusive use of Dr. Gabriella Gobbi’s groundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses […]
TRYP picks AstraZeneca’s Vaccine Development Partner
When AstraZeneca had to choose a development and manufacturing partner for their COVID vaccine, they chose AMRI. That’s why Tryp Therapeutics (CSE: TRYP) has chosen AMRI as their contract research and development partner. They’re the best in the business. AMRI… Who? Albany Molecular Research Institute (AMRI) is a global contract research and development firm with facilities in North America, […]
Psychedelic Wellness-Focused Company Delic to Acquire Ketamine Infusion Centers LLC
VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce it has entered into a binding letter agreement (the “Letter Agreement“) to acquire Ketamine Infusion Centers LLC (“KIC“). KIC is a limited liability corporation formed under the laws of Arizona, which owns and operates […]
“Psychedelics” is a buzz word on Wall Street, but much like legal cannabis or bitcoin and blockchain a decade ago, it remains greatly misunderstood as the market emerges. There was a time when psychedelics were only perceived as part of the illicit drug culture. That stigma is disappearing. Loaded with promise, the burgeoning market includes […]
Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the appointment of Josephine Wu, Founder and CIO at Aionious Management, Ltd., to the Company’s Board of Directors. Josh Bartch, Chairman and CEO […]
Pure Extracts Announces Submission for Class 1 Natural Product Number (NPN)
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic sector, is pleased to announce that it recently completed its new company registration with the Natural and Non-prescription Health Products Directorate (NNHPD) and received its […]
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has shared details of its comprehensive and rigorous therapist training programme for psilocybin therapy, in a paper jointly written with a group of academic researchers, and published in Frontiers in Psychiatry today. The […]
Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announces the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article – The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder – is published in Taylor and Francis.com. To review the Article, […]
Red Light Holland Announces Increase in Bought Deal Equity Financing to $10 Million
Red Light Holland Corp. (“Red Light Holland”) (CSE:TRIP), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has entered into an amended agreement with Eight Capital, pursuant to which Eight […]
Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman
La Jolla, CA – February 3, 2020 – Tryp Therapeutics (“Tryp”) (CSE: TRYP), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, needs is pleased to announce the appointment of Greg McKee as Executive Chairman. Mr. McKee joined the Board in January of 2021 and brings more […]
Bexson Biomedical Raises $4.8 Million In Oversubscribed Series A
Capital will be used to further develop the Company’s proprietary ketamine therapies and a wearable device for delivery of controlled substances SANTA BARBARA, Calif., Feb. 2, 2021 /PRNewswire/ — Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of […]
PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.
Toronto, Ontario–(Newsfile Corp. – February 2, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has completed the previously announced (see press releases dated January […]
Allied Completes Acquisition of Pacific Sun Fungi: A Leader in the Psilocybin Space
KELOWNA, British Columbia, Feb. 02, 2021 (GLOBE NEWSWIRE) — Allied Corp. (“Allied”) (OTCQB: ALID) – an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce a follow up to it’s press release of December 24th, 2020 announcing the signing of a letter of intent to […]
CannaGlobal Appoints World-Class Board and Announces Rebranding to GoodCap Wellness
GoodCap Wellness Inc. (“GoodCap” or the “Company”), a leading research and development company focused on the medical benefits of mushroom-derived compounds, today announced it has changed its corporate name to GoodCap Wellness Inc. The GoodCap Wellness brand identity embodies the Company’s strategy to be a world leader in psilocybin and mushroom-related drug and product development. […]
MindMed (NEO: MMED, OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company, streamlined its leadership team to further develop the company’s strategy of integrating its psychedelic clinical development programs with innovative digital technologies. As part of this, Stephen Hurst will retire from his co-CEO and Executive Chair positions but will remain on the board […]
Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.
Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce a strategic partnership with neuroscience and technology leader, HealthTech Connex Inc. Upon approval of the Company’s Licensed Dealer application, the Company’s subsidiary, Havn Labs, will be a […]
PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.
PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (“PharmaDrug“), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has completed the previously announced (see press releases dated January 12, 2021 and January 25, 2021) acquisition of Sairiyo Therapeutics Inc. […]
Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments
Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon”), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on license amendments issued to its clinical research organization, The Centre for Human Drug Research (CHDR). Entheon confirms that the CHDR, the Company’s Netherlands-based partner clinical research organization, has received […]
Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board
La Jolla, California–(Newsfile Corp. – February 2, 2021) – Tryp Therapeutics, a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical needs, is pleased to announce that it has added world renowned psychedelic scientist, Dr. Robin Carhart Harris to help lead its Scientific Advisory Board. Dr. Robin Carhart-Harris states, “I’m delighted to be […]
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received Conditional Approval to migrate and uplist its common shares with the NEO Exchange (“NEO”). Final approval is subject […]
Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an Exclusive Worldwide Patent and Know-how License Agreement (the “Agreement”) with The Queen’s University of Belfast […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products.
FSD Pharma is a publicly traded company on the Canadian Securities Exchange under the symbol HUGE. The Company, through its wholly-owned subsidiary FV Pharma Inc., holds an ACMPR license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). HUGE, made history on its first day of trading on the Canadian Securities […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
